Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Metformin  COVID-19 treatment studies for Metformin  C19 studies: Metformin  Metformin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 79% Improvement Relative Risk Case -44% Blanc et al. Metformin for COVID-19 Prophylaxis Is prophylaxis with metformin beneficial for COVID-19? Retrospective 179 patients in France Lower mortality (p=0.058) and more cases (p=0.12), not stat. sig. Blanc et al., GeroScience, doi:10.1007/s11357-021-00397-z Favors metformin Favors control
Therapeutic prevention of COVID-19 in elderly: a case–control study
Blanc et al., GeroScience, doi:10.1007/s11357-021-00397-z
Blanc et al., Therapeutic prevention of COVID-19 in elderly: a case–control study, GeroScience, doi:10.1007/s11357-021-00397-z
Jul 2021   Source   PDF  
  All Studies   Meta
Retrospective 179 patients in France exposed to COVID-19 showing, without statistical significance, a higher risk of cases, and a lower risk of mortality among cases with existing metformin treatment.
risk of death, 78.6% lower, RR 0.21, p = 0.06, treatment 1 of 14 (7.1%), control 25 of 75 (33.3%), NNT 3.8, COVID+.
risk of case, 43.7% higher, RR 1.44, p = 0.12, treatment 11 of 16 (68.8%), control 78 of 163 (47.9%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Blanc et al., 17 Jul 2021, retrospective, France, peer-reviewed, 22 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperMetforminAll
Abstract: GeroScience (2021) 43:2333–2343 ORIGINAL ARTICLE Therapeutic prevention of COVID‑19 in elderly: a case–control study Frederic Blanc · Cedric Waechter · Thomas Vogel · Benoit Schorr · Catherine Demuynck · Catherine Martin Hunyadi · Maxence Meyer · Denata Mutelica · Nadjiba Bougaa · Samira Fafi‑Kremer · Lidia Calabrese · Elise Schmitt · Delphine Imperiale · Catherine Jehl · Alexandre Boussuge · Carmen Suna · François Weill · Alexia Matzinger · Candice Muller · Patrick Karcher · Georges Kaltenbach · Erik Sauleau Received: 1 May 2020 / Accepted: 31 May 2021 / Published online: 17 July 2021 © American Aging Association 2021 Abstract COVID-19 is a particularly aggressive disease for the elderly as 86% of deaths related to COVID-19 occur in people over 65 years of age. Despite the urgent need for a preventive treatment, there are currently no serious leads, other than the vaccination. The aim of this retrospective casecontrol study is to find a pharmacological preventive treatment of COVID-19 in elderly patients. One-hundred-seventy-nine patients had been in contact with other COVID-19 patients at home or in hospital, of whom 89 had tested RT-PCR-positive (COVID-pos) for the virus and 90 had tested RT-PCR-negative (COVID-neg). Treatments within F. Blanc (*) · E. Sauleau ICube Laboratory, UMR 7357 and CNRS, University of Strasbourg, Strasbourg, France e-mail: C. Waechter · T. Vogel · B. Schorr · C. Demuynck · C. M. Hunyadi · M. Meyer · D. Mutelica · N. Bougaa · L. Calabrese · E. Schmitt · D. Imperiale · C. Jehl · A. Boussuge · C. Suna · F. Weill · A. Matzinger · C. Muller · P. Karcher · G. Kaltenbach Pôle de Gériatrie, La Robertsau Geriatric Hospital, University Hospital of Strasbourg, Strasbourg, France S. Fafi‑Kremer Virology Department, University Hospital of Strasbourg, Strasbourg, France 15 days prior to RT-PCR (including antihypertensive drugs, antipsychotics, antibiotics, nonsteroidal anti-inflammatory drugs, proton pump inhibitors (PPIs), oral antidiabetics (OADs), corticosteroids, immunosuppressants), comorbidities, symptoms, laboratory values, and clinical outcome were all collected. COVID-pos patients more frequently had a history of diabetes (P = .016) and alcoholism (P = .023), a lower leukocyte count (P = .014) and a higher mortality rate — 29.2% versus 14.4% — (P = .014) when compared to COVID-neg patients. Patients on PPIs were 2.3 times less likely (odds ratio [OR] = 0.4381, 95% confidence interval [CI] [0.2331, 0.8175], P = .0053) to develop COVID19 infection, compared to those not on PPIs. No other treatment decreased or increased this risk. COVID-pos patients on antipsychotics (P = .0013) and OADs (P = .0153), particularly metformin (P = .0237), were less likely to die. Thus, patients on treatment with PPI were less likely to develop COVID-19 infection, and those on antipsychotics or metformin had a lower risk of mortality. However, prospective studies, including clinical trials, are needed to confirm or not these findings. Keywords COVID-19 · Prevention · Elderly · Geriatrics · Proton pump inhibitors · Antipsychotics · Metformin Vol.:(0123456789) 13
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop